Palo Alto, CA
,
USA
·
North America
Vivo Capital is a Palo Alto-based healthcare and life sciences crossover investment firm managing more than $5 billion in assets, focused on investments in biopharmaceutical and medical technology companies across the US and Asia with a distinctive cross-border healthcare investment model. The firm invests at Series A, Series B, and growth stages with initial checks from $10 million to $75 million. BeiGene, the Chinese oncology biopharmaceutical company, is a major portfolio company listed on Nasdaq. Gracell Biotechnologies, the clinical-stage CAR-T therapy company, was acquired by AstraZeneca for $1.2 billion in 2023. Kineta, the clinical-stage company developing anti-cancer immune therapies, is a portfolio company. Legend Biotech completed a Nasdaq IPO. Beyond its original investments, the portfolio includes additional US and Asian biopharmaceutical companies.
Know when they open it, which slides they read, and when to follow up.
Pitchwise turns every shared deck into a live intelligence feed.
